Streptomycin: Mechanism and Impact on Bacterial Protein Synthesis

Streptomycin kills bacteria by locking onto the cell’s protein-making machinery and forcing it to misread the genetic instructions for building proteins. It binds to a specific part of the bacterial ribosome called the 30S subunit and distorts the site where the ribosome checks whether it is reading the genetic code correctly. The result is a flood of defective proteins that poison the cell from the inside out, making streptomycin not just a protein synthesis inhibitor but a trigger for a cascade of self-inflicted damage.

Where Streptomycin Binds on the Ribosome

Bacterial ribosomes are made of two major pieces, the small 30S subunit and the larger 50S subunit. Streptomycin targets the 30S subunit, and specifically a region of the ribosomal RNA (the 16S rRNA) known as the decoding center. This is the spot where the ribosome performs quality control during protein synthesis, checking that each incoming building block matches the genetic instructions encoded in the messenger RNA. Crystal structures of the 30S subunit bound to streptomycin show that the drug causes a significant local distortion of the 16S rRNA, including two critical bases, A1492 and A1493, that participate directly in recognizing the correct genetic code.¹ Earlier biochemical work demonstrated that streptomycin can bind to the 16S rRNA even when it has been stripped of all ribosomal proteins, confirming that the RNA itself is the primary target rather than any protein component of the ribosome.² Studies using radiolabeled streptomycin further showed that each 30S subunit carries binding sites for two streptomycin molecules on its 16S RNA.³

How Misreading Happens

During normal translation, the ribosome is remarkably accurate. When a transfer RNA (tRNA) carrying an amino acid approaches the decoding center, the ribosome checks whether that tRNA’s anticodon properly matches the codon on the messenger RNA. If the match is wrong, the tRNA is rejected and the ribosome waits for a correct one. Streptomycin warps this quality-control checkpoint. By distorting the geometry of the decoding site, the drug makes near-mismatches look acceptable and, paradoxically, makes correct matches slightly less stable.¹

The errors are not random. In experimental systems, streptomycin preferentially causes misreading at the third position of codons. One well-characterized example involved the erroneous insertion of lysine at positions that should have been asparagine, caused by the ribosome misreading a pyrimidine as a purine at the third codon position.⁴ This positional bias matters because the third codon position is normally the most tolerant of wobble, so streptomycin is essentially exploiting the position where the ribosome is already least stringent and pushing it past the point of useful accuracy.

Streptomycin Also Disrupts Translation Initiation

Misreading during the elongation phase of protein synthesis gets most of the attention, but streptomycin also interferes with the very start of translation. It can trigger the release of the initiator tRNA from the ribosomal initiation complex, the assembly that must form before a new protein can be built.⁵ By knocking out the first step of protein assembly, streptomycin does not just corrupt the proteins that get made; it also prevents some from being started at all. This double action, blocking initiation and corrupting elongation, helps explain why streptomycin is bactericidal (it kills bacteria) rather than merely bacteriostatic (slowing their growth).

From Misreading to Cell Death

A protein with a few wrong amino acids is not just non-functional; it can be actively destructive. The critical step in how streptomycin actually kills bacteria involves what happens to those misfolded, mistranslated proteins. Many bacterial proteins are designed to sit in or span the cell membrane. When these membrane proteins are built with the wrong amino acids, they misfold and jam into the membrane abnormally, punching holes in the cell’s protective barrier. This causes the membrane to become leaky, letting ions like potassium flood out of the cell.⁶

Researchers confirmed this connection by showing that when bacteria were able to rapidly degrade the aberrant proteins, the membrane resealed and the cells recovered potassium. But under normal conditions, the damage snowballs. The membrane damage also lets more streptomycin molecules flood into the cell, which in turn corrupts even more proteins, which causes even more membrane disruption. This self-amplifying loop is central to streptomycin’s lethality. Work published in Cell showed that mistranslation and misfolding of membrane proteins specifically are central to triggering oxidative stress and cell death from aminoglycosides like streptomycin.⁷

Why Penicillin and Streptomycin Work Better Together

One of the classic drug combinations in infectious disease is streptomycin paired with penicillin, particularly against enterococci, which are tough to kill with either drug alone. The explanation comes down to access. Enterococci have a natural barrier that limits how much streptomycin can get inside the cell. Penicillin, which attacks the cell wall, weakens that barrier. When bacteria are growing in the presence of penicillin, their uptake of streptomycin increases dramatically.⁸

The synergy works in one direction. Brief treatment with penicillin speeds up the subsequent killing by streptomycin and hastens streptomycin’s secondary uptake into cells. But brief treatment with streptomycin does not improve subsequent killing by penicillin. This asymmetry tells us the partnership depends on penicillin’s ability to damage the membrane barrier first, opening the door for streptomycin to flood in and reach more ribosomes.⁹ It also underscores that getting enough streptomycin to the ribosomes is often the rate-limiting step; once the drug reaches its target in sufficient quantity, the misreading cascade does the rest.

The Post-Antibiotic Effect

Even after streptomycin is removed from the environment, bacteria that have been exposed to it do not bounce back immediately. This lag, called the post-antibiotic effect, turns out to follow a surprisingly clean pattern. Researchers found that the recovery time after streptomycin exposure increases roughly exponentially with total antibiotic exposure, and that the total exposure (concentration multiplied by time) matters more than how the dose is divided up. A short burst of a high concentration and a longer soak in a lower concentration produce comparable delays in recovery as long as the total drug exposure is the same.¹⁰ At high streptomycin concentrations, bacterial populations actually continued to decline even after the drug was washed away, suggesting that the self-amplifying damage loop outlined earlier keeps running on its own for a while.

How Bacteria Resist Streptomycin

Bacteria have evolved several strategies to survive streptomycin exposure, and they fall into two broad categories: altering the target and chemically disabling the drug.

Changing the Target

The most common chromosomal route to resistance involves mutations in the gene for ribosomal protein S12, called rpsL. S12 sits near the streptomycin binding site and helps shape the decoding center. A single amino acid change in S12 can alter the binding pocket enough to block streptomycin from attaching or reduce its ability to distort the decoding site.¹¹ Mutations in the 16S rRNA gene itself can also confer resistance. Structural analysis of six different resistant mutants showed that base changes in a highly conserved region of the 16S rRNA create new hydrogen-bonding and base-stacking interactions that reshape the binding pocket.¹²

Disabling the Drug Chemically

Outside the ribosome, bacteria can produce enzymes that modify streptomycin so it can no longer bind effectively. One of the most important is streptomycin adenylyltransferase, which uses the cell’s energy currency (ATP) to attach a chemical group onto streptomycin, rendering it inactive.¹³ The gene encoding this enzyme, aadA, has been found across a range of bacterial species, including enterococci.¹⁴ Because these enzyme genes often sit on mobile genetic elements like plasmids, they can spread between species far more rapidly than chromosomal mutations can.

The Fitness Cost of Resistance and Why It Persists

A common assumption is that drug-resistant bacteria pay a price for their resistance: grow slower, compete poorly against sensitive neighbors, and eventually disappear when the antibiotic is removed. For streptomycin resistance, the picture is more complicated. Certain rpsL mutations (K42N and P90S in S12) do impair growth on rich media, consistent with expectations. But when the same mutants were grown on poorer carbon sources, they actually grew faster than wild-type bacteria.¹⁵ This means the fitness cost is not a fixed penalty but depends heavily on the environment.

The situation gets more troubling when bacteria carry resistance to multiple antibiotics simultaneously. In one study examining bacteria with combined resistance to streptomycin and rifampicin, 85% of the double-resistant strains showed no significant fitness cost in glucose minimal media. Roughly 65% of all tested double mutants were actually expected to outcompete sensitive bacteria even without any antibiotic present.¹⁶ This finding undermines the hopeful notion that we can simply stop using an antibiotic and wait for resistance to fade. In many real-world conditions, resistant bacteria have no competitive disadvantage to lose.

Streptomycin Dependence

Perhaps the strangest outcome of streptomycin resistance mutations is that some go too far. Instead of merely preventing streptomycin from distorting the decoding site, certain S12 mutations make the ribosome so rigid in its proofreading that it can barely function without streptomycin to loosen things up again. These streptomycin-dependent mutants literally need the drug to grow. In the thermophilic bacterium Thermus thermophilus, researchers isolated streptomycin-dependent and pseudo-dependent mutants, all resulting from single amino acid substitutions in the rpsL gene.¹⁷ This phenomenon is not just a laboratory curiosity. It reveals that the ribosome’s accuracy operates on a knife’s edge: too much fidelity is just as lethal as too little, and streptomycin, at low concentrations, can push an over-strict ribosome back into a functional range.

Side Effects in Humans

Streptomycin’s selectivity for bacterial ribosomes over human ribosomes is what makes it a useful drug, but it is not perfectly selective. The drug’s most well-known side effect is damage to the inner ear, which can cause hearing loss or balance problems. In laboratory models, streptomycin exposure caused measurable loss of cochlear hair cells within 24 hours, accompanied by activation of cell-death pathways including caspase-3 and PARP.¹⁸ Hair cells in the inner ear do not regenerate in humans, so the damage is permanent once it occurs. This is why streptomycin dosing requires careful monitoring and why its use has been largely supplanted by other antibiotics for conditions where alternatives exist.

Kidney toxicity is another recognized risk. In kidney cell cultures, streptomycin at standard concentrations abolished active transport across the cell layer, wiped out glucose reabsorption, and reduced the cells’ energy metabolism. Electron microscopy revealed severe reduction in the microvilli that carry out transport on the cell surface, even though the cells themselves stayed intact and their tight junctions were preserved.¹⁹ The drug essentially silenced the specialized functions of kidney cells without killing them outright, a pattern consistent with the clinical observation that aminoglycoside kidney damage is often reversible if the drug is stopped in time, unlike the ear damage.

How the Producer Organism Protects Itself

Streptomycin is a natural product, made by the soil bacterium Streptomyces griseus. This raises an obvious question: how does the organism that manufactures a ribosome-targeting antibiotic avoid killing itself? The answer is built into the same gene cluster that encodes the biosynthetic enzymes. Researchers identified a cluster of at least four genes (strR, strA, strB, and strC) involved in streptomycin production and self-protection. The strA gene encodes streptomycin 6-phosphotransferase, an enzyme that chemically tags streptomycin with a phosphate group, rendering it harmless to the producer’s own ribosomes.²⁰

The timing of this self-defense is tightly regulated. The resistance gene aphD, encoding the same phosphotransferase, is transcribed mainly by read-through from the strR promoter, which is controlled by a signaling molecule called A-factor. When A-factor triggers streptomycin production, it simultaneously activates the resistance gene, so the bacterium arms itself before the weapon is fully assembled.²¹ This coordinated “shield before sword” strategy has been observed in many antibiotic-producing organisms, and understanding it has practical value. The same enzymatic resistance mechanism that evolved in the producer has turned up in pathogenic bacteria, likely spread by horizontal gene transfer over millions of years of microbial warfare in soil environments.

Streptomycin’s Place in Tuberculosis History

No discussion of streptomycin is complete without acknowledging its role as the first antibiotic effective against tuberculosis. After its isolation from Streptomyces griseus in the 1940s, the development of a submerged culture technique for large-scale production enabled rapid animal testing and human clinical trials against Mycobacterium tuberculosis.²² The 1948 British Medical Research Council trial of streptomycin for pulmonary tuberculosis is widely regarded as one of the first properly randomized controlled trials in medicine. Streptomycin’s success against TB transformed public health, but it also delivered an early lesson in resistance: within months of widespread use, resistant TB strains appeared, forcing the development of combination therapy that remains the backbone of TB treatment today. That lesson, first learned with streptomycin, shaped the entire philosophy of modern antibiotic stewardship.